» Articles » PMID: 28338651

Dichotomy in Intrahepatic Cholangiocarcinomas Based on Histologic Similarities to Hilar Cholangiocarcinomas

Overview
Journal Mod Pathol
Specialty Pathology
Date 2017 Mar 25
PMID 28338651
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Intrahepatic cholangiocarcinomas were classified into two types based on their microscopic appearance. Tumors with histologic similarities to hilar cholangiocarcinomas (predominantly ductal adenocarcinomas with minor tubular components, if present, restricted to the invasive front) were defined as the perihilar type, whereas the others were classified as peripheral cholangiocarcinomas. Among the 47 cases examined in the present study, 26 (55%) were classified as the perihilar type, whereas 21 (45%) were the peripheral type. The perihilar type had higher pT stages and more frequently showed a periductal-infiltrating gross appearance and microscopic perineural infiltration than peripheral cholangiocarcinomas. The presence of low-grade biliary intraepithelial neoplasia in the adjacent bile ducts was only found in perihilar cholangiocarcinomas (6/21, 29%). The immunophenotype also differed between the two types with MUC5AC and MUC6 being more commonly expressed in the perihilar type. One-third of perihilar cholangiocarcinomas lacked the expression of SMAD4, suggesting SMAD4 mutations, whereas the loss of BAP1 expression and IDH1 mutations were almost restricted to the peripheral type (35 and 15%, respectively). Patients with perihilar cholangiocarcinoma had worse overall survival than those with peripheral cancer (P=0.027). A multivariate analysis identified the histologic classification as an independent prognostic factor (P=0.005, HR=3.638). Comparisons between intrahepatic and hilar cholangiocarcinomas also revealed that the molecular features and prognosis of perihilar cholangiocarcinomas were very similar to those of hilar cholangiocarcinomas. In conclusion, this histology-based classification scheme of intrahepatic cholangiocarcinomas will be useful and clinically relevant because it represents different underlying molecular features and has an independent prognostic value.

Citing Articles

Standardizing the reporting of cholangiocarcinoma: the society of abdominal radiology disease focused panel on cholangiocarinoma lexicon.

Marks R, Arif H, Antonietta Bali M, Brunsing R, M Cunha G, Khasawneh H Abdom Radiol (NY). 2025; .

PMID: 39775025 DOI: 10.1007/s00261-024-04769-9.


Classification of intrahepatic cholangiocarcinoma.

El Homsi M, Alkhasawneh A, Arif-Tiwari H, Czeyda-Pommersheim F, Khasawneh H, Kierans A Abdom Radiol (NY). 2024; .

PMID: 39643732 DOI: 10.1007/s00261-024-04732-8.


Histopathological growth pattern and vessel co-option in intrahepatic cholangiocarcinoma.

Li Z, Nguyen Canh H, Takahashi K, Le Thanh D, Nguyen Thi Q, Yang R Med Mol Morphol. 2024; 57(3):200-217.

PMID: 38960952 PMC: 11343874. DOI: 10.1007/s00795-024-00392-1.


Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.

Plum P, Hess T, Bertrand D, Morgenstern I, Velazquez Camacho O, Jonas C Clin Transl Med. 2024; 14(6):e1723.

PMID: 38877653 PMC: 11178519. DOI: 10.1002/ctm2.1723.


Recommendations on maximising the clinical value of tissue in the management of patients with intrahepatic cholangiocarcinoma.

Kendall T, Overi D, Guido M, Braconi C, Banales J, Cardinale V JHEP Rep. 2024; 6(6):101067.

PMID: 38699072 PMC: 11060959. DOI: 10.1016/j.jhepr.2024.101067.


References
1.
Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M . Genomic spectra of biliary tract cancer. Nat Genet. 2015; 47(9):1003-10. DOI: 10.1038/ng.3375. View

2.
Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C . An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340(6132):626-30. PMC: 3985613. DOI: 10.1126/science.1236062. View

3.
Baheti A, Tirumani S, Shinagare A, Rosenthal M, Hornick J, Ramaiya N . Correlation of CT patterns of primary intrahepatic cholangiocarcinoma at the time of presentation with the metastatic spread and clinical outcomes: retrospective study of 92 patients. Abdom Imaging. 2014; 39(6):1193-201. DOI: 10.1007/s00261-014-0167-0. View

4.
Shirabe K, Mano Y, Taketomi A, Soejima Y, Uchiyama H, Aishima S . Clinicopathological prognostic factors after hepatectomy for patients with mass-forming type intrahepatic cholangiocarcinoma: relevance of the lymphatic invasion index. Ann Surg Oncol. 2010; 17(7):1816-22. DOI: 10.1245/s10434-010-0929-z. View

5.
Tsai J, Huang W, Kuo K, Yuan R, Chen Y, Jeng Y . S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas. Histopathology. 2012; 61(6):1106-16. DOI: 10.1111/j.1365-2559.2012.04316.x. View